Clinuvel Pharmaceuticals Ltd (CUV) — Cash Flow Quality Index
Clinuvel Pharmaceuticals Ltd (CUV) has a Cash Flow Quality Index of 1.20x as of December 2025. Operating cash flow of AU$12.52 Million exceeds net income of AU$10.44 Million, indicating high earnings quality where cash backs reported profits. Explore cash efficiency ratio of Clinuvel Pharmaceuticals Ltd to assess how effectively this company generates cash.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Clinuvel Pharmaceuticals Ltd Cash Flow Quality Index (2017–2025)
Historical Cash Flow Quality Index for Clinuvel Pharmaceuticals Ltd across 9 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check CUV cash reinvestment to operating cash ratio to assess the company's total reinvestment commitment from operating cash flow.
Annual Cash Flow Quality Index for Clinuvel Pharmaceuticals Ltd (2017–2025)
Year-by-year earnings quality comparison for Clinuvel Pharmaceuticals Ltd. For live market cap and the full company financial profile, see Clinuvel Pharmaceuticals Ltd stock valuation.
| Year | Quality Index | Operating CF (AUD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | 1.14x | AU$41.10 Million | AU$36.17 Million | ▲ +9.3% |
| 2024 | 1.04x | AU$37.05 Million | AU$35.64 Million | ▼ -13.8% |
| 2023 | 1.21x | AU$36.91 Million | AU$30.60 Million | ▼ -36.8% |
| 2022 | 1.91x | AU$39.87 Million | AU$20.88 Million | ▲ +145.2% |
| 2021 | 0.78x | AU$19.26 Million | AU$24.73 Million | ▼ -17.4% |
| 2020 | 0.94x | AU$14.19 Million | AU$15.05 Million | ▼ -7.4% |
| 2019 | 1.02x | AU$18.46 Million | AU$18.13 Million | ▲ +15.1% |
| 2018 | 0.88x | AU$11.69 Million | AU$13.22 Million | ▼ -36.0% |
| 2017 | 1.38x | AU$9.92 Million | AU$7.18 Million | — |